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Abstract  Five  years  survival  of  lung  cancer  is  16%,  signiﬁcantly  lower  than  in  prostate  (99.9%),
breast (88.5%)  and  colon  (64.1%)  carcinomas.  When  diagnosed  in  the  surgical  stage  it  increases
to 50%  but  this  group  only  comprises  14--16%  of  the  cases.  DNA  methylation  has  emerged  as  a
potential cancer-speciﬁc  biomarker.  Hypermethylation  of  CpG  islands  located  in  the  promoter
regions of  tumour  suppressor  genes  is  now  ﬁrmly  established  as  an  important  mechanism  for
gene inactivation.
This  retrospective  study  included  40  squamous  cell  carcinomas  and  40  adenocarcinomas  in
various surgical  TNM  stages  to  deﬁne  methylation  proﬁle  and  possible  silencing  of  DNA  repair
genes --  MLH1  and  MSH2  --  using  Methylation-Speciﬁc  PCR  and  protein  expression  by  immunohis-
tochemistry  in  tumoural  tissue,  preneoplastic  lesions  and  respiratory  epithelium  with  normal
histological  features.
The  protein  expression  of  MLH1  and  MSH2  genes,  in  the  available  preneoplastic  lesions  and
in normal  cylindrical  respiratory  epithelium  appeared  reduced.  The  frequency  of  promoter
hypermethylation  found  on  these  DNA  repair  genes  was  elevated,  with  a  higher  prevalence
of methylation  of  MLH1  gene  in  72%  of  squamous  cell  carcinoma.  The  differences  are  not  so
obvious for  MSH2  promoter  hypermethylation.  No  correlation  was  found  among  the  status  of
methylation,  the  protein  expression  and  the  clinicopathological  characteristics.
With a  larger  study,  a  better  characterization  of  the  hypermethylation  status  of  neoplastic
and preneoplastic  lesions  in  small  biopsies  would  be  achieved,  inherent  to  tumour  histology,
heterogeneity  and  preservation,  and  ﬁnally  differences  in  the  study  population  to  elucidate
 of  altered  expression  of  the  hMLH1  and  hMSH.other possible  mechanisms
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Hipermetilac¸ão  Promotora  de  Genes  Reparadores  de  DNA  MLH1  e  MSH2
em  Adenocarcinomas  e  Carcinomas  de  Células  Escamosas  do  Pulmão
Resumo  A  sobrevivência  aos  cinco  anos  no  cancro  do  pulmão  é  de  16%,  signiﬁcativamente
inferior que  nos  carcinomas  na  próstata  (99,9%),  mama  (88,5%)  e  cólon  (64,1%).  Quando  diag-
nosticado na  fase  cirúrgica  aumenta  até  50%,  mas  este  grupo  é  apenas  constituído  por  14-16%
dos casos.  A  metilac¸ão  do  ADN  surgiu  como  um  potencial  marcador  biológico  especíﬁco  do  can-
cro. A  hipermetilac¸ão  das  ilhas  CpG  localizadas  nas  regiões  promotoras  de  genes  supressores  do
tumor está  agora  ﬁrmemente  estabelecida  como  um  mecanismo  importante  para  a  inativac¸ão
do gene.
Este  estudo  retrospetivo  incluiu  40  carcinomas  das  células  escamosas  e  40  adenocarcinomas
em vários  estádios  cirúrgicos  TNM  para  deﬁnir  o  perﬁl  da  metilac¸ão  e  o  possível  silenciamento  de
genes de  reparac¸ão  do  ADN  -  MLH1  e  MSH2  -  usando  metilac¸ão  PCR  especíﬁca  e  expressão  da  pro-
teína por  imuno-histoquímica  no  tecido  tumoral,  lesões  pré-neoplásicas  e  epitélio  respiratório
com características  histológicas  normais.
A expressão  da  proteína  dos  genes  MLH1  e  MSH2,  nas  lesões  pré-neoplásticas  disponíveis
e no  epitélio  respiratório  cilíndrico  normal,  pareceu  reduzida.  A  frequência  da  hipermetilac¸ão
promotora  encontrada  nestes  genes  reparadores  de  ADN  foi  elevada,  com  uma  maior  prevalência
da metilac¸ão  do  gene  MLH1  em  72%  de  carcinoma  de  células  escamosas.  As  diferenc¸as  não  são
tão óbvias  para  a  hipermetilac¸ão  do  promotor  MSH2.  Não  foi  encontrada  correlac¸ão  entre  o
estado de  metilac¸ão,  a  expressão  da  proteína  e  as  características  clínico-patológicas.
Com um  estudo  mais  amplo,  seria  alcanc¸ada  uma  melhor  caracterizac¸ão  do  estado  da
hipermetilac¸ão das  lesões  neoplásicas  e  pré-neoplásicas  em  pequenas  biopsias,  inerente  à  his-
tologia, heterogeneidade  e  preservac¸ão  do  tumor,  e,  ﬁnalmente,  às  diferenc¸as  na  populac¸ão
estudada  para  elucidar  outros  mecanismos  possíveis  da  expressão  alterada  do  hMLH1  e  hMSH.
© 2012  Sociedade  Portuguesa  de  Pneumologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
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Introduction
Epigenetics  of  human  cancer  has  been  overshadowed  by
human  cancer  genetics  since  1983.  Increasingly  visible  with
a  growing  understanding  of  speciﬁc  epigenetic  mechanisms
and  their  role  in  cancer,1 the  modiﬁcations  refer  to  a
number  of  molecular  mechanisms  that  regulate  gene  expres-
sion  without  changing  DNA  sequence2:  (1)  alteration  of
methylation  status  of  DNA  within  CpG  islands  (the  main
human  epigenetic  modiﬁcation)3;  (2)  covalent  modiﬁca-
tion  of  histone  tails;  (3)  gene  regulation  by  micro-RNA
(miRNA).
While  early  embryonic  cells  lack  methylation  (as  it  is
not  transmitted  via  the  germline),  methylation  is  essen-
tial  for  the  development  and  regulation  of  gene  expression
and  controls  expression  of  oncofetal  genes  in  postnatal  life
by  imprinted  genes  and  tissue-speciﬁc  gene  expression.2
This  perfect  equilibrium  in  normal  cells  is  transformed  in
cancer  cells.  DNA  methylation  is  believed  to  contribute  to
cancer  initiation  and  progression  by  gene  inactivation.  This
can  have  important  consequences  if  the  inactivated  genes
are  essential  for  the  control  of  normal  cell  growth,  dif-
ferentiation,  or  apoptosis.4 The  mechanisms  that  regulate
normal  and  aberrant  methylation  are  neither  fully  under-
stood  nor  are  the  mechanisms  of  methylation  that  interfere
with  transcription.4
The  mismatch  DNA  repair  (MMR)  system  is  composed  of
a  few  well-conserved  proteins.  The  essential  components
of  MMR  system,  MutS,  MutL,  MutH  and  Uvr,  were  identiﬁed
in  Escherichia  coli. In  addition,  all  eukaryotic  organisms,
including  humans,  have  MutS  homologs  and  MutL  homologs.
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phe  MLH1  and  MSH2  genes  provide  instructions  for  making
 protein  that  plays  an  essential  role  in  DNA  repair.  These
roteins  ﬁx  mistakes  that  are  made  when  DNA  is  copied
DNA  replication)  in  preparation  for  cell  division.  The  MLH1
rotein  joins  with  another  protein,  the  PMS2,  to  form  an
ctive  protein  complex.  This  protein  complex  coordinates
he  activities  of  other  proteins  that  repair  errors  during
NA  replication.  The  repairs  occur  by  removing  the  section
f  DNA  and  replacing  it  by  a  correct  DNA  sequence.  The
SH2  protein  joins  with  one  of  the  two  other  proteins,
he  MSH6  protein  or  the  MSH3  protein,  to  form  an  active
rotein  complex.  This  active  protein  complex  identiﬁes
laces  on  the  DNA  where  mistakes  have  been  made  during
NA  replication.
The  prognosis  of  lung  cancer  is  very  limited  by  the
ifﬁculties  of  diagnosing  early  stage  disease  amenable  to
urgery.  Only  10%  of  cases  can  beneﬁt  from  local  treat-
ent  with  long-term  survival.  Despite  much  progress  in  the
reatment  and  detection  methods  of  lung  carcinoma,
he  prognosis  remains  poor.  This  situation  is  mainly  the  result
f  metastases  which  are  present  in  more  than  two-thirds  of
atients  at  the  time  of  diagnosis.5,6
The  objectives  of  our  study  were  to  characterize
he  expression  of  DNA  repair  proteins  MLH1  and  MSH2
n  tumour  tissue,  precursor  lesions,  respiratory  epithelia
nd  parenchyma  of  80  clinically  well-characterized  NSCLC
atients  and  also  to  study  the  methylation  status  of  two  DNA
epair  genes  --  MLH1  and  MSH2, to  correlate  between  the
ethylation  status  of  the  promoters  of  MLH1  and  MSH2, and
heir  respective  protein  expression  and  clinicopathological
arameters.
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Table  1  MLH1  and  MSH2  primer  concentrations  after  optimization.
Gene  Sequence  Tm  (◦C)  G/C  (%)  Conc.  (M)  Amplicon  (Bp)
MSH2  M  Forward  61  63.2  0.2
5′ TCGTGGTCGGACGTCGTTC  3′ 64.2  56.5  0.1  114
M Reverse
5′ CAACGTCTCCTTCGACTACACCG  3′
U  Forward  59.3  41.7  0.4
5′ GGTTGTTGTGGTTGGATGTTGTTT  3′ 63.9  41.4  0.2  123
U Reverse
5′ CAACTACAACATCTCCTTCAACTACACCA  3′
MLH1  M  Forward 61  45.8  0.1
5′ ACGTAGACGTTTTATTAGGGTCGC  3′ 61.4 60  0.2 131
M Reverse
5′-CCTCATCGTAACTACCCGCG-3′
U  Forward  58.2  27.6  0.4
5′ TTTTGATGTAGATGTTTTATTAGGGTTG-3′ 61.0  45.8  0.2  142
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5′ ACCACCTCATCATAACTACCCACA  3′
aterials and methods
atients  and  tissue  samples
ll  biopsy  and  resection  specimens  were  reviewed  by  the
athology  Department  of  the  University  Hospital  of  Coimbra,
o  verify  non-small  cell  histology  of  the  lung  cancer  samples
nd  to  determine  the  histologic  subtype.  Histological  sub-
ypes  consisted  of  80  cases  of  surgically  staged  pulmonary
arcinomas  as  well  as  corresponding  non-neoplastic  and  pre-
eoplastic  tissue  of  adenocarcinomas  and  squamous  cell
arcinomas  of  the  lung.
Twenty-four  females  and  16  males  with  adenocarcinoma
ADC),  and  36  males  and  4  females  with  squamous  cell  car-
inoma  (SCC)  were  conﬁrmed  according  to  the  latest  World
ealth  Organization  Classiﬁcation  of  Lung  Cancer  (2004).7
he  average  age  was  64.9  ±  9.88  years  at  the  time  of  diag-
osis.
The  TNM  staging  was  applied  according  to  the  2010
NM  Classiﬁcation  of  Malignant  Tumours,  7th  Edition8:
hirty-nine  patients  had  Stage  I  disease,  19  had  Stage  II  and
 had  stage  III.
issue  microarrays  building
epresentative  areas  of  carcinoma,  preneoplastic  lesion
nd  normal  bronchial  epithelium  and  parenchyma,  were
arefully  selected  from  the  haematoxylin-eosin  slide,  and
arked  respectively  in  each  slide  and  the  each  formalin-
xed,  parafﬁn-embedded  block  of  tissue.  Tissue  microarrays
f  3  mm  were  performed  in  triplicate  in  tumour  and  normal
espiratory  epithelium  and  in  a  single  core  for  preneoplastic
esion,  included  on  the  same  slide.
nalysis  of  protein  expression:
mmunohistochemistry
HC  satins  for  hMLH1  and  hMLH2  were  performed  on  3  m
hick  sections  cut  from  parafﬁn-embedded  TMAs  blocks.
a
d
oommercially  available  antibodies  against  these  markers
ere  used  as  per  manufacturer’s  protocols.  Monoclonal
ntibodies  used  were  (clone  ZM001,  1:200,  Zymed)  for
LH1and  (clone  FE11,  1:40,  Zymed)  for  MSH2,  using  the
treptavidin--Biotin  Horseradish  Peroxidase  method.  Epitope
etrieval  using  microwave  heat  or  steam  pre-treatment  was
erformed  as  required.  Normal  endometrium  was  used  as
ositive  control.  The  normal  staining  pattern  for  both  MLH1
nd  MSH2  is  nuclear.  Lymphocytes  and  normal  bronchial
pithelium  were  used  as  internal  positive  control  as  follow:
ormal  expression  (>75%/+++);  Reduced  expression:  Nega-
ive  (≤10%/−) and  Positive  (>10--50%/+  or  50--75%/++).
Following  the  explained  score  it  was  possible  to  deﬁne
wo  deﬁnite  groups,  the  positive  when  present  +++/75%
uclear  expression  and  the  group  with  reduced  expression.
taining  results  were  examined  without  knowledge  of  the
tatus  of  the  molecular  analyses.
ethylation-speciﬁc  polymerase  chain  reaction
ssay for  the  hMLH1  and  hMSH2  genes
or  DNA  extraction,  areas  from  all  the  slides  correspond-
ng  to  the  principal  histological  patterns  were  selected.
he  tumour-rich  areas  were  manually  micro-dissected.  Five
0  M  sections  were  cut  from  the  parafﬁn  blocks  corre-
ponding  to  the  already  selected  areas  and  deparafﬁned  by
ylene  extraction.  The  resulting  tissue  pellets  were  digested
ith  Proteinase  K  at  56 ◦C  overnight.  The  genomic  DNA
as  isolated  using  QIAamp  DNA  MiniKit  according  to  the
anufacturer’  protocol  (Qiagen,  Valencia,  CA).  By  spec-
rophotometry  (Nanodrop  ND1000,  Thermo  Scientiﬁc,  USA)
he  purity  and  concentration  of  the  samples  were  veriﬁed.
The  promoter  methylation  status  of  the  MLH1  gene  of  all
umour  samples  and  of  the  MSH2  gene  of  tumour  samples
as  determined  by  chemical  treatment  with  sodium  bisulﬁte
nd  subsequent  methylation-speciﬁc  PCR  (MSP)  analysis  as
escribed.9
Two  sets  of  primers  were  speciﬁcally  designed  upstream
f  the  promoter  region  to  discriminate  methylated  from
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−.Hypermethylation  of  DNA  repair  genes  
unmethylated  alleles,  using  the  Methprimer  Software10
(Table  1).
The  bisulﬁte  modiﬁcation  was  performed  using  the  Epi-
tect  Bisulﬁte  Kit  (Qiagen  Valencia,  CA)  to  convert  all
unmethylated  cytosines  to  uracils,  while  leaving  methylated
cytosines  unaffected  (Table  2).
Modiﬁed  DNA  was  ampliﬁed  in  a  total  volume  of  110  L
containing  1×  NH4  buffer,  2  mM  of  MgCl2,  200  M  of  dNTPs,
1  U  Taq  DNA  Polymerase  (Bioline),  different  primer  pair
concentrations  were  used  after  optimization  (Table  1),
considering  that  we  are  working  with  FFPE  tissue,  an
optimization  procedure  confers  better  results.  PCR  was
performed  for  40  cycles  with  annealing  temperatures  of
61 ◦C  for  30  s and  primer  extension  at  72 ◦C  for  60  s  using
50  ng  bisulﬁte-modiﬁed  DNA.  All  PCRs  were  performed  with
positive  controls  for  both  unmethylated  and  methylated
alleles  and  no  DNA  control.  DNA  of  healthy  human  lym-
phocytes  served  as  positive  control  for  methylated  and
unmethylated  MLH1  and  MSH2  state.  The  ﬁrst  was  treated
with  Methyltransferase  (CpG  Methyltransferase  M.SssI)  (New
England  Biolabs),  and  subsequently  submitted  to  sodium
bisulﬁte  transformation  (Epitect  Bisulﬁte,  Qiagen),  the  sec-
ond  was  only  modiﬁed  with  sodium  bisulphite.  The  CpG
Methyltransferase,  M.SssI,  methylates  all  cytosine  residues
(C5)  within  the  double-stranded  dinucleotide  recognition
sequence  5′.  .  .CG.  .  .3′.
The  PCR  products  were  separated  on  a  4%  agarose  gel
containing  ethidium  bromide  and  visualized  under  UV  light,
and  its  size  estimated  by  comparison  with  a  DNA  Molecular
Weight  Marker  XIII  (50  bp  ladder)  (Roche).
Statistical  analysis
The  association  between  clinicopathological  variables
(pTNM,  gender,  age)  and  frequency  of  methylation  and  pro-
tein  expression  silencing  among  the  tumour  subtypes  was
assessed  using  the  Pearson  2 and  Fischer’s  exact  test.  All
tests  were  two-sided  and  the  level  of  signiﬁcance  was  set  at
p  <  0.05.
Results
Protein  expression  of  MLH1  and  MSH2  in  tissue
microarrays
We  investigated  MLH1  and  MSH2  expression  using  immuno-
histochemistry  analysis  in  tissue  microarrays  comprising  80
primary  NSCLC  patients,  that  were  respiratory  epithelium,
preneoplastic  lesion  (basal  cell  hyperplasia,  metaplasia,
dysplasia)  and  tumoural  patterns.  Following  the  explained
score  it  was  possible  to  deﬁne  two  deﬁnite  groups,  nor-
mal  expression  with  >75%/+++  nuclear  expression  and  the
group  with  reduced  expression  <75%/++.  After  applying
these  scores,  the  internal  control  of  lymphocytes  had  normal
expression  (data  not  shown)  but  tumour  adjacent  respiratory
epithelium  and  parenchyma  were  considered  reduced  for
both  MLH1  and  MSH2.  Twenty-three  cases  (57%)  of  ADC  for
MLH1  expression  and  27  cases  (67%)  for  MSH2,  had  reduced
expression;  in  SCC  29  cases  (72%)  for  MLH1  expression  and
25  cases  (62%)  for  MSH2  expression  had  reduced  expression.
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Table  3  Clinicopathological  distribution  of  gene  promoter  methylation  and  loss  of  expression  at  tumour  type  in  80  patients.
Patient’s age  ranging  64.9  ±  9.88  years  (63.4  years  --  adenocarcinoma  66.55  years  --  squamous  cell  carcinoma),  28  females  and
52 males.
Patient 
No/ag e 
Gender
(M/F) 
Tumour  
Type  
TNM
Stage 
MLH1 
Loss 
Express ion 
MLH1 
Methylatio n 
MSH2 
Loss 
Expression 
MSH2
Methylatio n 
1/73 M ADC pT1N0Mx IA     
2/71 F ADC T1NxMx 
 
    
3/69 M ADC pT2N0Mx IB     
4/75 M ADC pT1N2Mx; IIIA     
5/53   F AD C pT1N0 Mx IA        
6/76  M AD C pT2N0Mx IB        
7/62  M AD C pT1N1Mx IIA        
8/74   F AD C n.a .         
9/50   F AD C pT1N1Mx IIA         
10/68  F AD C pT1N0Mx IA        
11/57  F AD C pT2N0Mx IB        
12/51  M AD C pT1N1Mx IIA         
13/55  F AD C n. a.         
14/75  F AD C pT2N0Mx IB        
15/85  M AD C pT1NxMx 
 
       
16/63  F AD C pT1N2Mx IIIA        
17/67  F AD C n. a.         
18/48  M AD C n.a .         
19/71  M AD C pT2N1Mx IIB        
20/63  F AD C pT1N2Mx IIIA        
21/49  M AD C pT3N0Mx IIB        
22/80  F AD C pT1NxMx 
 
       
23/68  F AD C pT2N0Mx IB        
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Table  3  (continued  )
24/48 M ADC pT2N0Mx IB     
25/56 M ADC pT1N0Mx IA     
26/76 M ADC pT1N0Mx IA     
27/64  M AD C pT2N0Mx IB        
28/56  F AD C pT1N0Mx IA        
29/67 F ADC pT2N0Mx IB     
30/71  F AD C pT2N0Mx IB        
31/50 F ADC pT1N0Mx IA     
32/80  F AD C n. a.         
33/56  F AD C pT1N0Mx IA        
34/54  F AD C pT1N0Mx IA   n.d.    n.d. 
35/67  M AD C pT2N1Mx IIB   n.d.    n.d. 
36/62  F AD C pT1N1Mx IIA    n.d.    n.d. 
37/44  F AD C pT2N2Mx IIIA   n.d.    n.d. 
38/52  F AD C pT4N1Mx IIIB    n.d.    n.d. 
39/61  M AD C pT2N0Mx IB   n.d.    n.d. 
40/68  F AD C pT1NxMx 
 
  n.d.    n.d. 
41/66  M  SCC  pT1N0Mx IA        
42/69  M  SCC  pT1N0Mx IA        
43/68  M  SCC  pT2N0Mx IB        
44/70  M  SCC  pT2N0Mx IB        
45/73  M  SCC  pT2N0Mx IB        
46/65  M  SCC  pT3N0Mx IIB        
47/53  M  SCC  pT2N0Mx IB        
48/61  M  SCC  pT1N0Mx IA        
49/48  M  SCC  pT1N1Mx IIA         
50/65  M  SCC  pT2N0Mx IB        
51/53  M  SCC  pT1NxMx 
 
       
52/84  M  SCC  pT2N0Mx IB        
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Table  3  (continued  )
53/73 M SCC pT2N0Mx IB     
54/61  M  SCC  pT2N2Mx IIIA        
55/77  M  SCC  pT2N0Mx IB        
56/59  M  SCC  pT2N1Mx IIB        
57/52  M  SCC  pT2N0Mx IB        
58/72 M SCC n.a.     
59/55  M  SCC  pT2N1Mx IIB        
60/80 M SCC pT2N0Mx IB     
61/79  M  SCC  pT3N0Mx IIB        
62/74  M  SCC  n. a.         
63/50  M  SCC  pT3N1Mx IIIA        
64/80  M  SCC  pT1N0Mx IA        
65/73  M  SCC  pT2N1Mx IIB        
66/74  M  SCC  pT1N0Mx IA        
67/72  F  SCC  pT2N0Mx IB        
68/77  M  SCC  pT4N0Mx IIIB         
69/65  M  SCC  pT2N1Mx IIB        
70/65  M  SCC  pT3N0Mx IIB        
71/72  M  SCC  pT2N1Mx IIB        
72/68  M  SCC  pT2N1Mx IIB        
73/60  M  SCC  pT3N2Mx IIIA        
74/67  M  SCC  pT1N0Mx IA        
75/69  M  SCC  pT1N0Mx IA        
76/53  F  SCC  n.a .         
77/58  M  SCC  pT2N1Mx IIB        
78/71  M  SCC  pT3N0Mx IIB        
79/61  F  SCC  pT2N0Mx IB        
80/70  F  SCC  pT2N0Mx IB        
White grey denotes unmethylated and normal protein expression respectively, dark grey methylated promoter genes. M, male; F, female;
 size
3
p
m
T
i
pADC, adenocarcinoma; SCC, squamous cell carcinoma; T, tumour
n.d., not determined.
Co-reduction  of  both  MLH1  and  MSH2  was  found  in
8  cases  (19  ADC  and  19  SCCs),  according  with  Table  5,
robably  due  to  different  altered  epigenetic  or/and  genetic
echanisms  involved  in  down-regulation  of  gene  expression.
umour  cells  that  exhibited  an  absence  of  nuclear  staining
a
f; N, local metastasis; M, distant metastasis; n.a., not available;
n  the  presence  of  non-neoplastic  cells  and  inﬁltrating  lym-
hocytes  with  nuclear  staining  were  considered  to  have  an
bnormal  pattern.
In  normal  respiratory  epithelium  reduced  expression  was
ound  in  70%  MLH1  and  75%  MSH2  in  ADC,  and  100%  MLH1
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Figure  1  MLH1  IHC  expression  in  one  mixed  type  adenocarcinoma,  (A)  basel  cell  hyperplasia,  (B)  acinar  pattern  with  reduced
press
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oexpression (−),  (C)  bronchioloalveolar  pattern  with  normal  ex
MSH2 IHC  expression  in  epidermoid  carcinoma  in  situ  and  (E)  co
and  97%  in  MSH2  in  SCC,  to  study  this  we  would  need  cancer-
free  controls  to  explain  the  possible  time  required  to  acquire
the  additional  genetic  and  epigenetic  changes  that  promote
tumour  progression.
Basal  cell  hyperplasia  in  cases  of  adenocarcinoma  pre-
sented  normal  expression  of  MLH1  and  MSH2.  Squamous  cell
carcinomas  revealed  reduced  expression  of  MLH1  and  MSH2
in  72%  and  62.5%  respectively.  Fig.  1  represents  the  IHC
expression  heterogeneity.
MLH1  and  MSH2  methylation  status  in  tumour
samplesWe  examined  the  promoter  hypermethylation  status  of
MLH1  and  MSH2  genes  in  40  squaumous  cell  carcinoma
and  33  adenocarcinoma  using  MSP  assay  in  manually
o
n
c
mion  (+++)  and  (D)  solid  pattern  with  reduced  expression  (++);
onding  epidermoid  carcinoma  (F)  200×.
icrodissected  tissue.  40  DNA  samples  of  squamous  cell  car-
inoma  and  33  samples  of  adenocarcinoma  were  analyzed
Table  3).
We  observed  two  patterns  of  hypermethylation;  the  par-
ial  pattern  was  the  most  prevalent  (58.33%)  for  the  MLH1
ene  (M-U)  while  for  the  MSH2  gene  the  hypermethylation
ully  pattern  (M-M)  was  the  one  most  veriﬁed  (76.9%).
MLH1  methylation  pattern  seems  to  vary  substan-
ially  by  histological  type  (Table  3).  The  prevalence  of
LH1  promoter  hypermethylation  was  higher  in  squa-
ous  cell  carcinoma  (47.5%),  with  a correlation  (p  =  0.003)
etween  the  histological  subtype  and  the  methylation  status
f  the  promoter  of  MLH1  gene.  The  difference  is  not  so
bvious  in  MSH2  promoter  hypermethylation;  however  ade-
ocarcinoma  has  the  highest  number  of  cases  (42.4%).  No
orrelation  was  found  between  histological  subtype  and
ethylation  status  of  MSH2  (p  =  0.2699).
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Table  4  Promoter  hypermethylation  frequency  in  NSCLC  in
tumour tissues,  by  histological  types.
ADC  (N  =  33)  SCC  (N  =  40)
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Table  7  Correlation  of  MLH1  and  MSH2  methylation  levels
and respective  protein  expression  in  relation  to  the  clinico-
pathological  variables  of  NSCLC  tumours  (age,  gender  and
TNM stage).
Age  Gender  TNM  stage
NSCLC
MLH1  loss  expression 0.319 0.555 0.988
MLH1  methylation  0.077  0.920  0.133
MSH2 loss  expression  0.669  0.555  0.189
MSH2 methylation  0.737  0.139  0.562
a
m
f
s
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d
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m
e
i
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o
pMLH1  5  (15.2%)  19  (47.5%)
MSH2  14  (42.4%)  12  (30%)
According  to  the  relationship  between  the  frequency  of
ender  and  histological  subtype,  women  with  adenocarci-
oma  as  well  as  men  with  squamous  cell  carcinoma  have  a
igher  percentage  of  hypermethylation  of  MLH1  and  MSH2
romoters  (Table  4).
elationship  between  the  methylation  status
nd IHC  protein  expression
ccording  to  the  distribution  of  gene  promoter  methyla-
ion  and  loss  of  expression  at  tumour  type  in  80  patients,
o  statistical  correlation  was  observed  between  the  pro-
oter  methylation  and  expression  levels  in  tumour  samples,
 =  0.09  for  MLH1  and  p  =  0.894  for  MSH2  (Tables  5--7).
Moreover,  no  correlation  was  found  between  MLH1  and
SH2  methylation  levels  and  any  of  the  clinicopathologi-
al  characteristics  considered  (age,  gender,  TNM  stage  and
umour  histological  type)  (Table  7).
We  observed  two  patterns  of  hypermethylation;  the  par-
ial  pattern  was  the  most  prevalent  (58.33%)  for  the  MLH1
ene  (M-U)  while  for  the  MSH2  gene  the  hypermethylation
ully  pattern  (M-M)  was  the  one  most  veriﬁed  (76.9%).
iscussion
ost  clinical  studies,  have  recorded  moderate  to  high  ele-
ation  of  MSH2  expression  in  sporadic  tumours  like  colon,
rostate  or  bladder  while  there  is  substantial  reduction
o  near  loss  of  functional  MLH1  or  MSH2  protein  expres-
ion  in  ovarian,  lung  and  stomach  tumours  relative  to  their
atched  normal  tissues.11--13 Reduced  expression  of  MLH1
nd  MSH2  was  observed  in  respiratory  epithelia,  metaplasia
w
p
a
M
Table  5  Frequency  of  promoter  hypermethylation  in  NSCLC  tumo
ADC  
Female  (N  =  19)  Male  (N  =  14
MLH1  4  (80%)  1  (20%)  
MSH2 8  (57.1%)  6  (42.9%)  
Table  6  Correlation  between  MLH1  and  MSH2  promoter  hyperme
histochemistry  expression.
IHC  expression  MLH1  promoter  hypermethylation
M  
Normal  expression 5  
Reduced expression  19  
P 0.09  nd  dysplasia.  We  know  that  cancer  is  a  disease  involving
ultiple  pathways  and  genetic  lesions,  which  are  necessary
or  a  tumour  to  become  fully  established.  The  story  is  the
ame  for  epigenetic  lesions.  It  is  difﬁcult  to  explain  the  dif-
erential  rates  of  progression  of  premalignant  lesions  and
ifferences  in  behaviour  of  morphologically  similar  lesions.
eterogeneity  for  microsatellite  instability  (MSI)  and  pro-
oter  methylation  in  driving  these  phenomena  forward  may
xplain  this;  however,  no  previous  analysis  has  examined  this
n  detail.
Alterations  in  expression  of  MMR  proteins  MLH1  and  MSH2
ave  been  reported  in  a  variable  proportion  of  NSCLC  but
ery  few  studies  have  investigated  the  role  of  reduced
rotein  expression  in  precursor  lesions  of  NSCLC  or  have
nvestigated  their  potential  prognostic  signiﬁcance  in  inva-
ive  carcinomas.  More  recent  studies  have  identiﬁed  changes
n  methylation  in  the  oral  epithelium  of  smokers  and  linked
hese  changes  to  bronchial  epithelium.14,15
We  found  differences  concerning  the  pattern  of  methyl-
tion  of  MLH1  gene  depending  on  the  histological  typing  of
SCLC  (p  =  0.003)  and  within  the  subtype.  Fifteen  percent
f  the  ADC  cases  showed  hypermethylation  of  MLH1  com-
ared  with  47.5%  cases  of  methylated  SCC.  Although
e  found  no  signiﬁcant  differences  in  the  methylation
attern  of  MLH1  and  MSH2  genes  in  SCC,  ADC  has
 higher  frequency  of  MLH1  methylated  rather  than
SH2.
ur  tissue,  by  histological  type  and  gender.
SCC
)  Female  (N  =  4)  Male  (N  =  36)
2  (10.5%)  17  (89.5%)
3  (25%)  9  (75%)
thylation  and  its  possible  interference  in  respective  immuno-
 MSH2  promoter  hypermethylation
U  M  U
20  9  16
29  17  31
0.894
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In  patients  with  ADC  we  also  found  basal  cell  hyper-
plasia  that  presents  MLH1  and  MSH2.  Although  this  can
be  explained  by  the  fact  that  the  pathogenesis  of
adenocarcinoma  is  not  related  with  the  bronchus  and
therefore  with  basal  cells,  but  with  Clara  Cells  and  type-
II  pneumonocytes,  so  basal  cell  hyperplasia  and  also
metaplasia  are  not  required  to  have  reduced  protein
expression.16
Females  with  adenocarcinoma  were  signiﬁcantly  more
likely  to  have  methylated  MLH1  and  MSH2  compared  to
males.  Although,  these  differences  were  not  observed
in  squamous  cell  carcinoma,  males  were  more  likely  to
have  hypermethylation  of  MLH1  and  MSH2. These  substan-
tial  differences  have  not  been  consistently  noted  in  the
literature,15 at  least  on  the  genes  under  study,  perhaps
because  few  studies  have  been  stratiﬁed  by  histological  type
when  assessing  hypermethylation  differences  by  gender.15
Since  females  are  more  likely  to  have  adenocarcinomas  com-
pared  to  males,  differences  in  hypermethylation  frequency
due  to  gender  may  have  been  obscured  by  differences  due
to  histological  type.16
Hawes  et  al.  mentioned  in  their  recent  work  that  substan-
tial  differences  in  hypermethylation  by  gender  may  suggest
the  possibility  of  differential  pathways  and/or  risk  factors
for  NSCLC  between  genders,  with  respect  to  risk  factors,
especially  with  regards  to  the  effect  of  cigarette  smoking
as  well  as  survival  and  effectiveness  of  treatment.17,18 Hor-
monal  factors  may  account  for  these  differences,  although
the  mechanism  that  inﬂuences  the  methylation  status  in
NSCLC  remains  unclear.18
As  in  our  study,  Xinarianos  et  al.19 and  Cooper  et  al.,20 did
not  ﬁnd  any  correlation  between  reduced  MLH1  and  MSH2
expression  and  age,  gender,  tumour  differentiation  or  TNM
stage.
Most  of  the  studies  used  qualitative  methylation-speciﬁc
PCR  in  order  to  detect  DNA  methylation,  a  method  that  can
sometimes  lead  to  false  positive  results  and  does  not  distin-
guish  between  low  and  high  level  methylation.  Furthermore,
results  in  these  studies  have  been  inconsistent  due  to  vary-
ing  methylation  detection  protocols,  PCR  primers,  and  study
populations,  and  none  have  comprehensively  studied  more
than  10  genes.16,17
The  variability  in  results  that  we  observed  is  probably
due  to  a  number  of  technical  factors,  such  as  assay-
speciﬁc  differences  including  target  sites  of  CpG  island  loci,
primers  and  the  conditions  of  sodium  bisulﬁte  modiﬁca-
tion.  Promoter  hypermethylation  is  one  of  the  mechanisms
responsible  for  the  genes  silencing,4 although  in  this  work
no  correlation  was  found  between  MLH1  and  MSH2  pro-
moter  methylation  and  IHC  expression  in  tumour  samples
(Tables  6  and  7).
To  better  understand  the  role  of  MMR  system  in  the
tumourigenesis  of  carcinomas  of  the  lung,  we  conclude
that  there  is  a  real  need  for  a  more  robust  study
covering  the  differences  inherent  to  tumour  histology,  het-
erogeneity  and  preservation,  and  ﬁnally  differences  in  the
study  population  (age,  gender  and  number  of  subtyped  cases
beyond  NSCLC),  to  elucidate  other  possible  mechanisms  of
altered  expression  of  the  hMLH1  and  hMSH2, including  loss
of  heterozygosity,  chromosomal  instability  and  imbalance
mutations  in  genes  of  the  MMR  system,8 and  alterations  in
mRNA  transcription.
129
thical disclosures
rotection  of  human  and  animal  subjects.  The  authors
eclare  that  no  experiments  were  performed  on  humans  or
nimals  for  this  study.
onﬁdentiality  of  data.  The  authors  declare  that  they  have
ollowed  the  protocols  of  their  work  centre  on  the  publica-
ion  of  patient  data  and  that  all  the  patients  included  in  the
tudy  received  sufﬁcient  information  and  gave  their  written
nformed  consent  to  participate  in  the  study.
ight  to  privacy  and  informed  consent.  The  authors
eclare  that  no  patient  data  appear  in  this  article.
unding
unded  by  a  grant  from  CIMAGO,  Faculty  of  Medicine,  Uni-
ersity  of  Coimbra,  Portugal.
onﬂicts of interest
he  authors  have  no  conﬂicts  of  interest  to  declare.
eferences
1. Feinberg AP. The epigenetics of cancer etiology. Semin Cancer
Biol. 2004;14:427--32.
2. Brambilla E, Gazdar A. Pathogenesis of lung cancer
signalling pathways: roadmap for therapies. Eur Respir J.
2009;33:1485--97.
3. Esteller M. Aberrant DNA methylation as a cancer-inducing
mechanism. Annu Rev Pharmacol Toxicol. 2005;45:629--56.
4. Digel W,  Lübbert M. DNA methylation disturbances as novel ther-
apeutic target in lung cancer: preclinical and clinical results.
Crit Rev Oncol Hematol. 2005;55:1--11.
5. Kim JS, Han J, Shim YM, Park J, Kim D-H. Aberrant methylation
of H-Cadherin (CDH13) promoter is associated with tumor pro-
gression in primary nonsmall cell lung carcinoma. Am Cancer
Soc. 2005;104:1825--33.
6. Fujiwara K, Fujimoto N, Tabata M, Nishii K, Matsuo K, Hotta K,
et al. Identiﬁcation of epigenetic aberrant promoter methyla-
tion in serum DNA is useful for early detection of lung cancer.
Clin Cancer Res. 2005;11:1219--25.
7. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathol-
ogy and genetics of tumours of the lung, pleura, thymus and
heart, WHO Classiﬁcation of Tumours. Lyon: IARC Press; 2004.
8. Sobin Leslie H, Gospodarowicz MK, Wittekind C. TNM classiﬁca-
tion of malignant tumours. 7th ed. Oxford, UK: Wiley-Blackwell;
2009.
9. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB.
Methylation-speciﬁc PCR a novel PCR assay for methylation sta-
tus of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821--6.
0. Li LC, Dahiya R, Methprimer:. designing primers for methylation
PCRs. Bioinformatics. 2002;18:1427--31.
1. Momparler RL, Ayoub J. Potential of 5-aza-2′-deoxycytidin
(Decitabine) a potent inhibitor of DNA methylation for ther-
apy of advanced non-small cell lung cancer. Lung Cancer.
2001;34:S111--5.2. Schwartsmann G, Schunemann H, Gorini CNF, Ferreira Filho AF,
Garbino C, Sabini G, et al. A phase I trial of cisplatin plus
decitabine, a new DNA-hypomethylating agent, in patients with
advanced solid tumours and a follow-up early phase II evaluation
31
1
1
1
1
1
1
20  
in patients with inoperable non-small cell lung cancer. Invest
New Drugs. 2000;18:83--91.
3. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P,
Busby L, Wheeler R, et al. Evaluation of a 7-day continuous
intravenous infusion of decitabine: inhibition of promoter-
speciﬁc and global genomic DNA methylation. J Clin Oncol.
2005;23:3897--905.
4. Vageli D, Daniil Z, Dahabreh J, Karagianni E, Vamvakopoulou
DN, Ioannou MG, et al. Phenotypic mismatch repair
hMSH2 and hMLH1 gene expression proﬁles in primary
non-small cell lung carcinomas. Lung Cancer. 2009;64:
282--8.
5. Bhutani M, Pathak AK, Fan YH, et al. Oral epithelium as a surro-
gate tissue for assessing smoking-induced molecular alterations
in the lungs. Cancer Prev Res. 2008;1:39--44.
6. Hawes SE, Stern JE, Feng Q, Wiens Q, Wiens LW,  Rasey JS,
et al. DNA hypermethylation of tumors from non-small cell lungA.  Gomes  et  al.
cancer (NSCLC) patients is associated with gender and histologic
type. Lung Cancer. 2010;69:172--9.
7. Cerfolio Rj, Bryant AS, Scott E, Sharma M, Robert F, Spencer
SA, et al. Women with pathologic state I, II and III non-
small cell lung cancer have better survival than men. Chest.
2006;130:1796--802.
8. Caldarella A, Crocetti E, Comin CE, Janni A, Pegna Al, Paci E.
Gender differences in non-small cell lung cancer: a population
based study. Eur J Surg Oncol. 2007;33:763--8.
9. Xinarianos G, Liloglou T, Prime W,  et al. hMLH1 hMSH2 expres-
sion correlates with allelic imbalance on chromosome 3p in
non-small cell lung carcinomas. Cancer Res. 2000;60:4216--21.
0. Cooper WA,  Kohonen-Corish MRJ, Chan C, Kwun SY, McCaughan
B, Kennedy C, Sutherland RL, et al. Prognostic signiﬁcance of
DNA repair proteins MLH1, MSH2 and MGMT expression in non-
small cell lung cancer and precursor lesions. Histopathology.
2008;52:613--22.
